These distribution agreements will enable the company to expand its sales network to a total of 14 sales agencies. Paradigm BioDevices is one of the agencies, and the others were not named in the press release.
“We are particularly enthusiastic following the signing of this partnership agreement. Implanet’s product range, and notably its JAZZ implant, will supplement our offering to include a product with unique features. We look forward to providing our customers this breakthrough spine technology, in a market that we have successfully addressed for over twenty years,” said Mike O’Neil, president and CEO of Paradigm BioDevices in the press release.
More Articles on Devices:
5 Key Results: LDR’s Mobi-C Artificial Disc Replacement vs. ACDF
FDA Clears AccelSPINE’s Next Generation Minimally Invasive Spine System
Global Medical Device Market to Grow at 6.2% Annually Until 2018
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
